Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 55Recurrence 14Neoplasms, Plasma Cell 9Primary Myelofibrosis 3Polycythemia Vera 3Neoplasms 3Waldenstrom Macroglobulinemia 2Plasmacytoma 2Myeloproliferative Disorders 2Hematologic Diseases 2Thrombocytosis 1Thrombocythemia, Essential 1Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Sarcoma 1Pancreatic Neoplasms 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Glioma 1Ependymoma 1Central Nervous System Neoplasms 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Neoplasms × pomalidomide × Clear all
NCT01946477 2026-05-22

POM MM 014

Celgene

Phase 2 Completed
186 enrolled 17 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasmacytoma

NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

NCT03567616 2021-06-30

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

AbbVie

Phase 2 Terminated
8 enrolled 12 charts
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡